We are live on ! Find out more

Perspective Therapeutics

CATX

Market cap $357M

3.13 USD

-0.03

0.95%

At close Updated Aug 27, 10:32 AM EDT

1 day

-0.95%

5 days

-3.69%

1 month

10.99%

3 months

-24.76%

6 months

-42.04%

Year to date

12.19%

1 year

-13.3%

5 years

-51.85%

10 years

-58.27%

About: Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.

Employees: 166

Healthcare Medical Instruments & Supplies

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 40%

Neutral 50%

Negative 10%

Zacks Investment Research

Are Medical Stocks Lagging Perspective Therapeutics, Inc. (CATX) This Year?

Here is how Perspective Therapeutics (CATX) and Bristol Myers Squibb (BMY) have performed compared to their sector so far this year.

Are Medical Stocks Lagging Perspective Therapeutics, Inc. (CATX) This Year?

Zacks Investment Research

4 Biotech Stocks Likely to Outpace Q2 Earnings Estimates

Medical sector earnings are off to a strong start, and four biotech companies are positioned to potentially beat estimates in upcoming quarterly results.

4 Biotech Stocks Likely to Outpace Q2 Earnings Estimates

Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2026 Financial Results

SEATTLE, July 31, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that it will report its second quarter 2026 financial results and provide a business update on Monday, August 10, 2026 after the market closes. The press release will be available on the newsroom section of the Company's website at https://perspectivetherapeutics.com/newsroom/press-releases.

Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2026 Financial Results

Zacks Investment Research

Perspective Therapeutics (CATX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

After losing some value lately, a hammer chart pattern has been formed for Perspective Therapeutics (CATX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Perspective Therapeutics (CATX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Perspective Therapeutics Receives European Orphan Medicinal Product Designation for [212Pb]VMT-α-NET in GEP-NETs

SEATTLE, July 28, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that the European Commission (EC) has granted orphan medicinal product designation for [²¹²Pb]VMT-α-NET for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The designation follows a positive opinion from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA).

Perspective Therapeutics Receives European Orphan Medicinal Product Designation for [212Pb]VMT-α-NET in GEP-NETs

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Oral Presentation at the ESMO Congress 2026

SEATTLE, July 17, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company's [212Pb]VMT-α-NET program have been accepted for presentation as detailed below at the European Society of Medical Oncology (ESMO) Congress 2026 taking place October 23 to 27, 2026 in Madrid, Spain. ESMO plans to release further details for regular abstracts on October 19, 2026.

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Oral Presentation at the ESMO Congress 2026

Zacks Investment Research

Is Perspective Therapeutics, Inc. (CATX) Stock Outpacing Its Medical Peers This Year?

Here is how Perspective Therapeutics (CATX) and Charles River Laboratories (CRL) have performed compared to their sector so far this year.

Is Perspective Therapeutics, Inc. (CATX) Stock Outpacing Its Medical Peers This Year?

Perspective Therapeutics Appoints Paul Lyne, Ph.D., as Chief Science Officer; Co-Founder Michael K.

Dr. Lyne joins Perspective from Merck KGaA with more than 25 years in biopharmaceuticals and contributions to more than 30 oncology programs Dr. Lyne joins Perspective from Merck KGaA with more than 25 years in biopharmaceuticals and contributions to more than 30 oncology programs

Perspective Therapeutics Appoints Paul Lyne, Ph.D., as Chief Science Officer; Co-Founder Michael K.

Proactive Investors

Perspective Therapeutics doses first brain tumor patient in expanded radiopharmaceutical trial

Perspective Therapeutics Inc. (NYSE-A:CATX) has treated the first patient with a type of brain tumor called meningioma using its experimental drug [212Pb]VMT-a-NET, broadening a clinical trial that previously focused only on a different cancer type known as neuroendocrine tumors. The new arm of the Phase 1/2a study, called LEMONaDE, aims to assess how safe the treatment is and whether it shows early signs of shrinking tumors in meningioma patients.

Perspective Therapeutics doses first brain tumor patient in expanded radiopharmaceutical trial

Perspective Therapeutics Expands Therapeutic Focus Areas; First Patient Dosed with [212Pb]VMT-α-NET in the Meningioma Cohort of a Phase 1/2a Study

SEATTLE, June 03, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that the first meningioma patient was dosed with [212Pb]VMT-α-NET in the Company's ongoing Phase 1/2a study.

Perspective Therapeutics Expands Therapeutic Focus Areas; First Patient Dosed with [212Pb]VMT-α-NET in the Meningioma Cohort of a Phase 1/2a Study

See News Rankings

Price charts implemented using Lightweight Charts™